Fig. 6
Effect of MAPKK inhibition on HUVEC viability pretreated for 24 h with AS or FS and then exposed for 24 h to 32 % O2 (mild hyperoxic conditions) or to 21 % O2 (normoxic conditions), as evaluated by the trypan blue assay. Cells were incubated with the pharmacological MAPKK inhibitor PD98059 (25 μM) for 1 h before AS or FS addition. Cultures treated with FS and exposed to normoxic conditions were used as negative controls. Each point represents mean ± SD of three experiments. Data represent percentage of viable cells (mean percentage) calculated from the number of viable cells in each sample versus negative control. *P < 0.05 versus FS-treated cells exposed to normoxic conditions. °P < 0.05 versus FS-treated cells exposed to mild hyperoxic conditions. § P < 0.05 versus AS-treated cells exposed to normoxic conditions. # P < 0.05 versus AS-treated cells exposed to mild hyperoxic conditions. AS, human serum obtained after Medox® capsules consumption; FS, human serum obtained immediately before Medox® capsules consumption